Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Acquired by Davidson Capital Management Inc.

Davidson Capital Management Inc. increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.6% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 6,896 shares of the pharmaceutical company’s stock after buying an additional 365 shares during the quarter. Davidson Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $2,777,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Northwest Investment Counselors LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter worth about $25,000. Highline Wealth Partners LLC acquired a new position in Vertex Pharmaceuticals in the 3rd quarter worth about $27,000. Dunhill Financial LLC boosted its position in Vertex Pharmaceuticals by 70.6% during the third quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. acquired a new stake in Vertex Pharmaceuticals in the fourth quarter valued at approximately $30,000. Finally, Legacy Investment Solutions LLC purchased a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at approximately $33,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Down 3.1 %

Shares of VRTX opened at $455.22 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company’s 50-day moving average price is $435.95 and its 200 day moving average price is $462.13. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on VRTX. Morgan Stanley increased their target price on Vertex Pharmaceuticals from $450.00 to $459.00 and gave the company an “equal weight” rating in a research report on Tuesday. Oppenheimer downgraded shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, December 19th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research note on Friday, January 31st. Royal Bank of Canada raised their target price on Vertex Pharmaceuticals from $402.00 to $407.00 and gave the company a “sector perform” rating in a research report on Tuesday. Finally, Citigroup initiated coverage on Vertex Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $575.00 price objective for the company. Ten research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $505.29.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.